200 related articles for article (PubMed ID: 16645163)
1. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.
Rudelius M; Pittaluga S; Nishizuka S; Pham TH; Fend F; Jaffe ES; Quintanilla-Martinez L; Raffeld M
Blood; 2006 Sep; 108(5):1668-76. PubMed ID: 16645163
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
Moosburner M; Alibegovic L; Hasselmann K; Gaiderov A; Hildebrand J; Philippou-Massier J; Blum H; Fischer L; Dreyling M; Silkenstedt E
Hematol Oncol; 2023 Dec; 41(5):858-868. PubMed ID: 37300279
[TBL] [Abstract][Full Text] [Related]
3. Novel targeted therapies for mantle cell lymphoma.
Alinari L; Christian B; Baiocchi RA
Oncotarget; 2012 Feb; 3(2):203-11. PubMed ID: 22361516
[TBL] [Abstract][Full Text] [Related]
4. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL; Brown F; Long M; Weigel C; Koirala S; Chung JH; Pray B; Villagomez L; Hinterschied C; Sircar A; Helmig-Mason J; Prouty A; Brooks E; Youssef Y; Hanel W; Parekh S; Chan WK; Chen Z; Lapalombella R; Sehgal L; Vaddi K; Scherle P; Chen-Kiang S; Di Liberto M; Elemento O; Meydan C; Foox J; Butler D; Mason CE; Baiocchi RA; Alinari L
Blood; 2023 Sep; 142(10):887-902. PubMed ID: 37267517
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway.
Wang J; Xu Z; Lai Y; Zhang Y; Zhang P; Mu Q; Yang S; Sheng L; Ouyang G
Curr Mol Med; 2024 Apr; ():. PubMed ID: 38659267
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.
Vann KR; Pal D; Smith AL; Sahar NE; Krishnaiah M; El-Gamal D; Kutateladze TG
Mol Biomed; 2022 Jan; 3(1):2. PubMed ID: 35031886
[TBL] [Abstract][Full Text] [Related]
7. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma.
Dal Col J; Zancai P; Terrin L; Guidoboni M; Ponzoni M; Pavan A; Spina M; Bergamin S; Rizzo S; Tirelli U; De Rossi A; Doglioni C; Dolcetti R
Blood; 2008 May; 111(10):5142-51. PubMed ID: 18339899
[TBL] [Abstract][Full Text] [Related]
8. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract][Full Text] [Related]
9. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
Lantermans HC; Ma F; Kuil A; van Kesteren S; Yasinoglu S; Yang G; Buhrlage SJ; Wang J; Gray NS; Kersten MJ; Treon SP; Pals ST; Spaargaren M
Leukemia; 2024 Mar; ():. PubMed ID: 38454120
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Phillips TJ; Avigdor A; Gurion R; Patti C; Corradini P; Tani M; Mehta A; Lossos IS; Zinzani PL; Thieblemont C; Jurczak W; Zheng F; Rappold E; Zhao W; Jiang P; Johnson P
Blood Adv; 2024 Feb; 8(4):867-877. PubMed ID: 38113459
[TBL] [Abstract][Full Text] [Related]
11. Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.
Jain N; Mamgain M; Chowdhury SM; Jindal U; Sharma I; Sehgal L; Epperla N
J Hematol Oncol; 2023 Aug; 16(1):99. PubMed ID: 37626420
[TBL] [Abstract][Full Text] [Related]
12. First Report of FARSA in the Regulation of Cell Cycle and Survival in Mantle Cell Lymphoma Cells via PI3K-AKT and FOXO1-RAG1 Axes.
Feng M; Yang K; Wang J; Li G; Zhang H
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675119
[TBL] [Abstract][Full Text] [Related]
13. Rafting on the Plasma Membrane: Lipid Rafts in Signaling and Disease.
Isik OA; Cizmecioglu O
Adv Exp Med Biol; 2023; 1436():87-108. PubMed ID: 36648750
[TBL] [Abstract][Full Text] [Related]
14. A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells.
Ghaderi A; Zhong W; Okhovat MA; Aschan J; Svensson A; Sander B; Schultz J; Olin T; Österborg A; Hojjat-Farsangi M; Mellstedt H
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297673
[TBL] [Abstract][Full Text] [Related]
15. Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.
Manni S; Pesavento M; Spinello Z; Saggin L; Arjomand A; Fregnani A; Quotti Tubi L; Scapinello G; Gurrieri C; Semenzato G; Trentin L; Piazza F
Front Cell Dev Biol; 2022; 10():935023. PubMed ID: 36035991
[TBL] [Abstract][Full Text] [Related]
16. Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.
Profitós-Pelejà N; Santos JC; Marín-Niebla A; Roué G; Ribeiro ML
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205606
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma.
Zhong M; Tan J; Pan G; Jiang Y; Zhou H; Lai Q; Chen Q; Fan L; Deng M; Xu B; Zha J
Front Oncol; 2021; 11():780118. PubMed ID: 34926293
[TBL] [Abstract][Full Text] [Related]
18. Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma.
Manni S; Fregnani A; Quotti Tubi L; Spinello Z; Carraro M; Scapinello G; Visentin A; Barilà G; Pizzi M; Dei Tos AP; Vianello F; Zambello R; Gurrieri C; Semenzato G; Trentin L; Piazza F
Front Oncol; 2021; 11():733848. PubMed ID: 34722279
[TBL] [Abstract][Full Text] [Related]
19. Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape.
Sadeghi L; Wright AP
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200679
[TBL] [Abstract][Full Text] [Related]
20. P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.
Zhou XR; Li X; Liao LP; Han J; Huang J; Li JC; Tao HR; Fan SJ; Chen ZF; Li Q; Chen SJ; Ding H; Yang YX; Zhou B; Jiang HL; Chen KX; Zhang YY; Huang CX; Luo C
Acta Pharmacol Sin; 2022 Feb; 43(2):457-469. PubMed ID: 33850273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
